Colitis Clinical Trial
Official title:
Colitis Prospective Cohort Study: Determining the Aetiologies of Acute Colitis and Developing a Diagnostic Score to Identify Patients Requiring Specific Investigations
The aetiologies of computed tomography-diagnosed acute colitis remain surprisingly unknown. Moreover, no diagnostic tool or clinical score allow to quickly determine or at least stratify the exact cause of colitis in patients admitted at an Emergency Ward and to direct them to the appropriate therapeutic care. The aims of the present study are to describe the presentation and aetiologies of acute colitis, and to develop diagnostic methods to guide patients admitted for acute colitis to the appropriate therapeutic care, notably colonoscopy.
Colitis is the generic term that refers to an inflammation of a segment of the colonic tract
confirmed by computed tomography. This pathology represents approximately 100-150 admissions
per year in the Division of Digestive Surgery of the University Hospitals of Geneva.
The aetiologies of colitis are numerous and include all pathologies having the ability to
cause the inflammation and thickening of the colon wall. Colites are classified according to
their aetiologies into: infectious colitis (bacterial, parasitic or viral), inflammatory
chronic bowel diseases (ulcerative colitis, Crohn's disease, others), ischaemic colitis and
iatrogenic colitis (non-steroidal anti-inflammatory drugs, others). The aetiologies of
colitis affect therapeutic care, since patients with infectious colitis will improve with
appropriate antibiotics, those with inflammatory chronic bowel disease will require the
introduction of an immunosuppressive therapy, and those with ischaemic colitis will only need
a supportive treatment and a careful evaluation to detect any progression to bowel
perforation that would prompt for surgery.
Therefore, numerous investigations are performed to determine the precise aetiology of
colitis.
At the University Hospitals of Geneva, as well as in other centres, a microbiological
analysis of faeces (routine PCR assay looking for Shigella spp., Salmonella spp. and
Campylobacter spp.; PCR for Clostridium difficile as well as cultures for Vibrio spp. and
Yersinia spp. (in option)) are performed in first intention. If these assays yield to the
absence of a potential pathogen, a colonoscopy is performed to look for: 1) a tumour, 2) a
chronic inflammatory bowel disease or 3) an ischaemic colitis. Patients in whom no aetiology
can be found to explain the colonic inflammation are given a diagnosis of undetermined
colitis.
However, the respective prevalences of the different aetiologies of colitis remain
surprisingly unknown. Similarly, no diagnostic tool or clinical score allow to quickly
determine or at least stratify the exact cause of colitis in patients admitted in the
Emergency Ward and to direct them to the appropriate therapeutic care. As a consequence, all
patients admitted with a diagnosis of computed tomography-proven colitis are subjected to
broad-spectrum antibiotics associated with a 5-10 days hospitalisation for monitoring and
investigations. Patients with negative microbiological examination of the stools will benefit
from an early colonoscopy, a procedure that carries significant risks of complications and
generates high costs. Moreover, the difficulties in the early identification of patients
requiring endoscopy for suspected inflammatory chronic bowel disease or cancer may delay or
even contribute to miss these diagnoses, especially if the acute phase of inflammatory
chronic bowel disease has passed.
Considering the lack of evidences regarding the therapeutic care of colitis, we plan to
constitute a cohort of 200 patients admitted for a first episode of computed
tomography-proven colitis at the University Hospitals of Geneva. We will collect data related
to 1) the history, clinical and para-clinical presentations at admission, 2) the results of
the aetiological investigations; and we will complete the investigations by performing 3) a
detailed microbiological examination of the stools using an accurate and rapid multi-array
PCR assay (FilmArray, Biofire Diagnostics, Salt Lake City, USA), as well as 4) a dosage of
faecal calprotectin (a marker of bowel inflammation).
The aims of the present study are to describe the presentation and aetiologies of colitis,
and to develop diagnostic methods to guide patients admitted for acute colitis to the
appropriate therapeutic care, with the objective to generate savings by shortening hospital
stays and by better prescribing additional tests, including colonoscopy. We therefore think
that an adequate and early patient stratification has important medical and economical values
in this setting.
We expect: 1) to diagnose a higher proportion of infectious colitis than currently reported,
and this within a shorter turnaround time, a finding that could serve as a basis to discuss
and implement a reduction in the rate of colonoscopies, 2) to identify predicting factors,
including faecal calprotectin, which would help distinguishing patients who require an
endoscopic evaluation from others, among patients with negative microbiological examination
of the stools.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00272818 -
Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
|
||
Completed |
NCT01369355 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
|
Phase 3 | |
Completed |
NCT00533078 -
Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies
|
Phase 2 | |
Terminated |
NCT00184171 -
Treatment of Microscopic Colitis
|
N/A | |
Recruiting |
NCT05333978 -
Optoacoustic Detection of Inflammation Using MSOT Device
|
N/A | |
Not yet recruiting |
NCT06424769 -
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
|
N/A | |
Recruiting |
NCT02768038 -
Intestinal Microbiome and Chronic Inflammatory Bowel Disease
|
||
Recruiting |
NCT04272307 -
MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.
|
||
Completed |
NCT05514561 -
FIT and Fecal Calprotectin in Patients With Chronic Lower GI Symptoms
|
||
Completed |
NCT00072943 -
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
|
Phase 2 | |
Recruiting |
NCT02687724 -
Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis
|
Phase 4 | |
Completed |
NCT02647866 -
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT01326013 -
A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel
|
Phase 2 | |
Not yet recruiting |
NCT05726396 -
A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis
|
Phase 2 | |
Completed |
NCT05414552 -
ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
|
||
Recruiting |
NCT04407247 -
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
|
Phase 1/Phase 2 | |
Completed |
NCT01369329 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
|
Phase 3 | |
Completed |
NCT01369342 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
|
Phase 3 | |
Terminated |
NCT00936585 -
NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease
|
N/A | |
Completed |
NCT06074874 -
Intestinal Biomarker Analysis After ECP for ICI Colitis
|